A case report of severe visceral beta2-microglobulin-derived amyloidosis without obvious joint symptoms or radiological findings in a chronic hemodialyzed patient with systemic lupus erythematosus.
Beta-2-microglobulin-derived amyloidosis (Abeta2M amyloidosis) is a critical complication for patients undergoing long-term renal replacement therapy. Osteoarticular lesions, rather than visceral organs, are susceptible to this type of amyloidosis, and the visceral form seems to occur at a relatively late stage. Herein, we report a case of severe visceral Abeta2M amyloidosis without obvious joint symptoms or radiological findings in a chronic hemodialyzed patient who had received long-term treatment with glucocorticoid steroids for systemic lupus erythematosus. It should be noted that prominent visceral Abeta2M amyloidosis can develop without any osteoarticular symptoms or radiological abnormalities in dialyzed patients undergoing prolonged glucocorticoid therapy.
Koda
Ryo
R
Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Nagaoka Red Cross Hospital, 1-757 Asahimachi-dori, Chuo-ku, Niigata, Japan. ryokouda@image.ocn.ne.jp
Yamazaki
Hajime
H
Kazama
Junichiro
J
Ito
Tomoyuki
T
Saeki
Takako
T
Emura
Iwao
I
Miyamura
Syoji
S
Narita
Ichiei
I
Gejyo
Fumitake
F
D000686:Amyloidosis / Q000209:etiology* / Q000503:physiopathology; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy; D008181:Lupus Nephritis / Q000628:therapy; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects*; D012720:Severity of Illness Index; D013997:Time Factors; D001613:beta 2-Microglobulin / Q000378:metabolism*
D005938:Glucocorticoids; D001613:beta 2-Microglobulin